Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables grows, but more slowly than its trailing trend

Q1 FY2026 accounts receivables of $742K rose 991.2% year over year, behind the +5438.2% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +253.5% a year.

Context

  • Accounts receivables amounted to 78.4% of revenue in FY2025, up 78.3 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +991.2% toward the trailing-twelve-month pace of +5438.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$742K+210.4% QoQ
Last fiscal yearDec 2025
$6.14M+30790.0% YoY
LTMMar 2026
$6.81M+5438.2% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+991.2%——
1 year+30790.0%——
3-year CAGR+253.5%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
6.14M USD
Year-over-year change
+30790.0%
4-year CAGR
+153.3%

Accounts Receivables vs competitors

How ACRS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5438.2% is the highest of 4, against a peer median of +44.2%.
  • Accounts receivables amounts to 81.4% of revenue for ACRS, versus a peer median of 1.7%.
ACRS Competitors
Accounts Receivables for ACRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$7.86M USD+44.2%—3.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.81M USD+5438.2%+253.5%81.4%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$2.07M USD+38.7%+209.4%—
IFRXInflaRx N.V.LTM Mar 2026€1.95M EUR+3826.6%—6648.5%
TRAXFirst Tracks Biotherapeutics IncFY2025$0 USD———
ALMSAlumis Inc. Common StockLTM Jun 2026$0 USD——0.0%
ATTOAttovia Therapeutics, Inc.FY2025$0 USD——0.0%
IMUXImmunic, Inc.LTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD———
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ACRS) —+44.2%+209.4%1.7%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Depreciation & Amortization923K797K863K807K454K
Deferred Income Tax752K0(367K)00
Stock-Based Compensation14.06M15.04M20.54M10.86M12.38M
Change in Working Capital(1.34M)(1.2M)9.39M10.92M2.67M
Accounts Receivables149K139K186K(20K)6.14M
Inventory00000
Accounts Payables3.66M368K(1.47M)(4.19M)8.45M
Other Working Capital(5.15M)(1.7M)10.68M15.13M(11.91M)
Other Non-Cash Items24.34M4.7M(20.27M)89.41M2.3M
Operating Cash Flow(52.13M)(67.57M)(78.33M)(20.08M)(47.11M)
Capital Expenditures(308K)(605K)(1.31M)(121K)(111K)
Acquisitions (Net)167.32M(13.23M)000
Purchases of Investments(235.15M)(164.75M)(135.68M)(119.98M)(39.73M)
Sales of Investments67.83M177.99M183.2M86.14M89.04M
Other Investing Activities(167.32M)13.23M0(35.81M)(833K)
Investing Cash Flow(167.63M)12.63M46.22M(69.77M)48.37M
Debt Repayment(11.48M)0000
Common Stock Issued238.2M72.74M26.71M74.91M0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.67M)123K(8K)(377K)(5.86M)
Financing Cash Flow225.05M72.87M26.71M74.54M(5.86M)
Effect of Forex Changes00000
Net Change in Cash5.29M17.93M(5.4M)(15.31M)(4.61M)
Free Cash Flow(52.44M)(68.17M)(79.63M)(20.2M)(47.11M)

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.